For example, delivery of IL-2/anti-IL-2-antibody complexes in pre-clinical studies stimulates Treg expansion and reduces disease in models of type 1 diabetes (T1D), experimentally induced autoimmune encephalomyelitis (EAE), collagen-induced arthritis, and angiotensin II-induced aortic stiffening (61–64). The gene discussed is AGT; the disease is type 1 diabetes mellitus.